Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • ROBERT BUTORA
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
  • JEANNE HAGGERTY
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • CHRISTOPHER E. WILCOX
    Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
 Lobbying activity 7
Pharmacy

Drug importation, prescription drug safety, value and access.

Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794).

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem